Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209430 | 0.86 | MAPT (0.44) | LMNAIDO1NPC1RAB9AALDH1A1 | |
| SCHEMBL8005599 | 0.84 | LMNA (0.67) | LMNAIDO1HTTNPC1RAB9A | |
| SCHEMBL777661 | 0.80 | IDO1 (0.47) | LMNAIDO1HTTLOXL2MAPK1 | |
| SCHEMBL15962378 | 0.79 | LMNA (0.41) | LMNAIDO1HTTMAPK1TDP1 | |
| SCHEMBL487139 | 0.78 | ALDH1A1 (0.55) | IDO1HTTLOXL2NPC1RAB9A | |
| SCHEMBL21765871 | 0.78 | HRH3 (0.42) | LMNAIDO1NPC1RAB9ABCHE | |
| SCHEMBL576909 | 0.78 | IDO1 (0.54) | IDO1HTTLOXL2TDP1NPC1 | |
| SCHEMBL515186 | 0.76 | MAPT (0.56) | LMNAIDO1TDP1NPC1RAB9A | |
| SCHEMBL10299392 | 0.76 | IDO1 (0.52) | LMNAIDO1MAPK1TDP1NPC1 | |
| SCHEMBL775008 | 0.75 | IDO1 (0.47) | LMNAIDO1HTTLOXL2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115651017-B | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2025-05-27 | — | — | CN | claimed |
| CN-115651017-A | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2023-01-31 | — | — | CN | claimed |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | claimed |
| EP-2725024-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-04-30 | — | — | EP | claimed |
| CN-115651017-B | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2025-05-27 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-11616253-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2023-03-28 | — | — | US | disclosed |
| CN-115651017-A | Method for selectively preparing benzyl or alkyl phosphine oxide compound based on benzyl thioether derivative | 中南大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220278370-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-09-01 | — | — | US | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| CN-1149191-C | Azetidine derivatives, Preparation and medicines containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-05-12 | — | — | CN | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| CN-1316991-A | Azetidine derivatives, preparation and medicines containing them | AVENTIS PHARMA SA (FR) | 2001-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | LMNA 4732/4885IDO1 1307/4885HTT 4598/4885 |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | LMNA 462/4885IDO1 442/4885HTT 3470/4885 |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | LMNA 3302/4885IDO1 529/4885HTT 1457/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | LMNA 1681/4885IDO1 1872/4885HTT 1247/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | LMNA 4494/4885IDO1 2152/4885HTT 3165/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | LMNA 4140/4885IDO1 911/4885HTT 926/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | LMNA 3266/4885IDO1 391/4885HTT 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.